Skip to content

Study Details

Testing Spesolimab for Adults with Hidradenitis Suppurativa

(IRB#: IRB_00167413)

Hidradenitis Suppurativa is a skin condition that causes painful lumps and soars on parts of the body such as the armpit. This study will test a drug called Spesolimab to treat adults with this disease. The study wants to see if the drug will help people with this disease and is safe. People in this study will be randomly chosen to be treated with Spesolimab or a placebo for 16 weeks. The study drug and placebo are taken as infusions (a liquid drug given under the skin) for 4 weeks at the beginning of participation. Then the drug is given as an injection (liquid drug given instantly into the skin) for the remainder of the study. After 16 weeks all participants will be given the study drug. Being in this study requires 31 study visits at the clinic for a little over a year. Medical tests will be done during the study to track the health of participants.

I AM INTERESTED

  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18 years and older
  • Diagnosis of Hidradenitis Suppurativa
  • Current conditions (painful lump and soar) of the disease on at least 2 specific parts of the body
  • Willing and able to use specific birth control
  • Able to attend in person at the study clinic

Exclusion Criteria

  • Willing and able to stop using any other drug that may interfere with Spesolimab
  • Prior use of Spesolimab
  • Major surgery 12 weeks before participation
  • Specific chronic infections including HIV
  • Pregnant or nursing

Will I be paid for my time?

Yes

For more information contact:

Sean Wentland

sean.wentland@hsc.utah.edu

  801-213-3427

IRB#: IRB_00167413

PI: Jamie Rhoads

Department: DERMATOLOGY

Approval Date: 2024-03-20 06:00:00

Specialties: Dermatology

Last Updated: 6/8/23